Drugs / Trifluridine/Tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07549412 Comparator | May 2026 → Oct 2029 expected | colorectal cancer | EMD Serono Research & Development Institute, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549412 ↗ |
| Route | Oral | “FTD-TPI, tablet, administered orally” NCT07549412 ↗ |